Posttransplant anemia in solid organ recipients

Transplantation Reviews

Volumn 24, Issue 2, 2010, Pages 89-98

  Blosser, Christopher D ^a   Bloom, R D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; AZATHIOPRINE; ERYTHROCYTE STIMULATING AGENT; MYCOPHENOLIC ACID; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; CARDIOVASCULAR DISEASE; CAUSAL ATTRIBUTION; CHRONIC KIDNEY DISEASE; DIET SUPPLEMENTATION; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MACROCYTIC ANEMIA; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; QUALITY OF LIFE; REVIEW; SURGICAL MORTALITY; TREATMENT RESPONSE;

EID: 77950799531     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2010.01.006     Document Type: Review

References (55)

1. WHO Nutritional anemia. World Health Organization Technical Report Series No. 405 1968, Switzerland, World Health Organization, Geneva.
2. National Kidney Foundation: KDOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease. Am J Kidney Dis 2001, 37(suppl 1):S182-S238.
3. The Renal Association Treatment of Adults and Children with Renal Failure. Standards and Audit Measures 2002, Royal College of Physicians of London and the Renal Association, London, UK. 3rd ed.
4. Revised European Best Practices Guidelines-anaemia evaluation. Nephrol Dial Transplant 2004, 19(Suppl 2):ii2-ii5.
5. Imoagene-Oyedeji A.E., Rosas S.E., Doyle A.M., Goral S., Bloom R.D. Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality. J Am Soc Nephrol 2006, 17:3240-3247.
6. Taegtmeyer A.B., Rogers P., Breen J.B., Barton P.J., Banner N.R., Yacoub M.H. The effects of pre- and post-transplant anemia on 1-year survival after cardiac transplantation. J Heart Lung Transplant 2008, 27:394-399.
7. Guitard J., Ribes D., Kamar N., Muscari F., Lavayssiere L., Suc B., et al. Predictive factors for anemia six and twelve months after orthotopic liver transplantation. Transplantation 2006, 81:1525-1531.
8. End A., Stift A., Wieselthaler G., Griesmacher A., Schlecta B., Koppensteiner R., et al. Anemia and erythropoietin levels in lung transplant recipients. Transplantation 1995, 60:1245-1251.
9. Yorgin P.D., Scandling J.D., Belson A., Sanchez J., Alexander J., Andreoni K.A. Late post-transplant anemia in adult renal transplant recipients. an under-recognized problem. Am J Transplant 2002, 2:429-435.
10. Vanrenterghem Y., Ponticelli C., Morales J.M., Abramowicz D., Baboolal K., Eklund B. Prevalence and management of anemia in renal transplant recipients: a European Survey. Am J Transplant 2003, 3:835-845.
11. Mix T.C., Kazmi W., Khan S., Ruthazer R., Rohrer R., Pereira J.G. Anemia: a continuing problem following kidney transplantation. Am J Transplant 2003, 3:1426-1433.
12. Gill J.S., Mix C.H., Pereira B.J. Glomerular fltration rate and the prevalence of chronic kidney disease among transplant recipients in the United States. Am J Transplant 2002, 2:417A. (abstr).
13. Chadban S.J., Baines L., Polkinghorne K., Jefferys A., Dogra S., Kanganas C., et al. Anemia after kidney transplantation is not completely explained by reduced kidney function. Am J Kidney Dis 2007, 49:301-309.
14. Sinnamon K.T., Courtney A.E., Maxwell A.P., McNamee P.T., Savage G., Fogarty D.G. Level of renal function and serum erythropoietin levels independently predict anaemia post-renal transplantation. Nephrol Dial Transplant 2007, 22:1969-1973.
15. Kuypers D.R.J., de Jonge H., Naesens M., de Loor H., Halewijck E., Dekens M., et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008, 30:673-683.
16. Borrows R., Chusney G., Loucaidou M., James A., Lee J., Tromp J.V., et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 2006, 6:121-128.
17. Al-Uzri A., Yorgin P.D., Kling P.J. Anemia in children after transplantation: etiology and the effect of immunosuppressive therapy on erythropoiesis. Pediatr Transplant 2003, 7:253-264.
18. Friend P., Russ G., Oberbauer R., Murgia M.G., Tufveson G., Chapman J., et al. Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function. Transpl Int 2007, 20:754-760.
19. Gralla J., Wiseman A.C. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transpantation: improved 3-year graft and patient survival in recent era. Transplantation 2009, 87:1712-1719.
20. Maiorano A., Stallone G., Schena A., Infante B., Pontrelli P., Schena F.P., et al. Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation 2006, 82:908-912.
21. Augustine J.J., Knauss T.C., Schulak J.A., Bodziak K.A., Siegel C., Hricik D.E. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004, 4:2001-2006.
22. Thaunat O., Beaumont C., Chatenoud L., Lechaton S., Mamzer-Bruneel M.F., Varet B., et al. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 2005, 80:1212-1219.
23. Vanrenterghem Y., Claes K., Montagnino G., Fieuws S., Maes B., Villa M., et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008, 85:209-216.
24. Molnar M.Z., Czira M., Ambrus C., Szeifert L., Szentkiralyi A., Beko G., et al. Anemia is associated with mortality in kidney-transplanted patients-a prospective cohort study. Am J Transplant 2007, 7:818-824.
25. Winkelmayer W.C., Chandraker A., Brookhart A., Kramar R., Sunder-Plassmann G. A prospective study of anaemia and long-term outcomes in kidney transplant recipients. Nephrol Dial Transplant 2006, 21:3559-3566.
26. Gleissner C.A., Murat A., Schafer S., Klingenberg R., Koch A., Remppis A., et al. Reduced hemoglobin after heart transplant is no independent risk factor for survival but is associated with impaired renal function. Transplantation 2004, 77:710-717.
27. Djamali A., Becker Y.T., Simmons W.D., Johnson C.A., Premasathian N., Becker B.N. Increasing hematocrit reduces early posttransplant cardiovascular risk in diabetic transplant recipients. Transplantation 2003, 76:816-820.
28. Moore J., He X., Cockwell P., Little M.A., Johnston A., Borrows R. The impact of hemoglobin levels on patient and graft survival in renal transplant recipients. Transplantation 2008, 86:564-570.
29. Rigatto C., Parfrey P., Foley R., Negrijn C., Tribula C., Jeffery J. Congestive heart failure in renal transplant recipients: risk factors, outcomes and relationship with ischemic heart disease. J Am Soc Nephrol 2002, 13:1084-1090.
30. Astor B.C., Coresh J., Heiss G., Pettitt D., Sarnak M.J. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk In Communities (ARIC) Study. Am Heart J 2006, 151:492-500.
31. Van Jaarsveld C.H., Ranchor A.V., Kempen G.I., Coyne J.C., van Veldhuisen D.J., Sanderman R. Epidemiology of heart failure in a community-based study of subjects aged > or = 57 years: incidence and long-term survival. Eur J Heart Fail 2006, 8:23-30.
32. Silverberg D.S., Wexler D., Iaina A., Schwartz D. The interaction between heart failure and other heart diseases, renal failure and anemia. Semin Nephrol 2006, 26:296-306.
33. Abbud-Filho M., Adams P.L., Alberu J., Cardella C., Chapman J., Cochat P., et al. A report of the Lisbon Conference on the Care of the Kidney Transplant Recipient. Transplantation 2007, 83:S1-S22.
34. KDIGO Clinical Practice Guidelines for the Care of Kidney Transplant Recipients. Am J Transplant 2009, 9(Suppl 3):S97-S101.
35. Grimm P.C., Sinai-Trieman L., Sekiya N.M., Robertson L.S., Robinson B.J., Fine R.N., et al. Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 1990, 38:12-18.
36. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006, 17:17-25.
37. Levin A., Thompson C.R., Ethier J., Carlisle E.J., Tobe S., Mendelssohn D., et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999, 34:125-134.
38. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990, 300:573-578. Canadian Erythropoietin Study Group 1990.
39. Evans R.W., Rader B., Manninen D.L. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990, 263:825-830. for the Cooperative Multicenter EPO Clinical Trial Group.
40. Evans R.W. Recombinant human erythropoietin and the quality of life of end-stage renal disease patients: a comparative analysis. Am J Kidney Dis 1991, 18(Suppl 1):62-70.
41. Kawada N., Moriyama T., Ichimaru N., Imamura R., Matsui I., Takabatake Y., et al. Negative effects of anemia on QOL and its improvement by complete correction of anemia by administration of recombinant human EPO in posttransplant patients. Clin Exp Nephrol 2009, 13:355-360.
42. Muirhead N., Cattran D.C., Zaltman J., Jindal K., First M.R., Boucher A., et al. Safety and efficacy of recombinant human EPO in correcting the anemia of patients with chronic renal allograft dysfunction. JASN 1994, 5:1216-1222.
43. Riano-Galan I., Malaga S., Rajmil L., Ariceta G., Navarro M., Loris C., et al. Quality of life of adolescents with end-stage renal disease and kidney transplant. Pediatr Nephrol 2009, 24:1561-1568.
44. Ayus J.C., Go A.S., Valderrabano F., Verde E., de Vinuesa S.G., Achinger S.G., et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10g/dL. Kidney Int 2005, 68:788-795.
45. Parfrey P.S., Lauve M., Latremouille-Viau D., Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol 2009, 4:755-762.
46. Pazzuoli A, Silverberg DS, Iovine F, Calabro A, Campagna MS, Gallotta M, et al. Effects of B-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with cardiorenal anemia syndrome. Am Heart J 2007;154:645.e9-645.e15.
47. Singh A.K., Szcech L., Tang K.L., Barhart H., Sapp S., Wolfson M., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
48. Drueke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdoughall I.A., Tsakiris D., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071-2084.
49. Ritz E., Laville M., Bilous R.W., O'Donoghue D., Scherhag A., Burger U., et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007, 49:194-207.
50. Pfeffer M.A., Burdmann E.A., Chen C.Y., Cooper M.E., de Zeeuw D., Eckardt K.U., et al. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. NEJM 2009, 361:2019-2032.
51. Becker B.N., Becker Y.T., Leverson G.E., Heisy D.M. Erythropoietin therapy may retard progression in chronic renal transplant dysfunction. Nephrol Dial Transplant 2002, 17:1667-1673.
52. National Kidney Foundation KDOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease. Am J Kidney Diseases 2006, 47(Suppl 3):S110-116.
53. US Food and Drug Administration and Center for Drug Evaluation and Research: Information for Healthcare Professionals: erythropoiesis stimulating agents (ESA) Available at:, Accessed November 4, 2009. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126481.htm.
54. Kamar N., Rostaing L. Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation 2008, 85:1120-1124.
55. Chhabra D., Grafals M., Skaro A.I., Parker M., Gallon L. Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol 2008, 3:1168-1174.